a corresponding viral transmembrane protein wherein the complex contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and the viral transmembrane protein.--

--33. (Amended) A vaccine which comprises a prophylactically effective amount of the protein encoded by a nucleic acid which comprises a nucleotide segment having a sequence encoding a complex comprising a viral surface protein and a corresponding viral transmembrane protein wherein the complex contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and the viral transmembrane protein.--

--46. (Amended) A mutant HIV-1 envelope protein which is encoded by a nucleic acid which comprises a nucleotide segment having a sequence encoding a complex comprising a viral surface protein and a corresponding viral transmembrane protein wherein the complex contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and the viral transmembrane protein.--

Remarks

Applicants have hereinabove canceled claims 1-29, 31-32, 34-43, 47-80 and 83-86 without prejudice or disclaimer to applicants' rights to pursue the subject matter of these claims in a later-filed application and amended claims 30, 33 and 46. Support for these